TY - JOUR
T1 - Glucagon-Like Peptide 1 Receptor Agonists
T2 - A Medication for Obesity Management
AU - Taha, Mohamad B.
AU - Yahya, Tamer
AU - Satish, Priyanka
AU - Laird, Rachel
AU - Agatston, Arthur S.
AU - Cainzos-Achirica, Miguel
AU - Patel, Kershaw V.
AU - Nasir, Khurram
N1 - Funding Information:
Dr. Nasir is on the advisory board of Amgen, Novartis, and Medicine Company, and his research is partly supported by the Jerold B. Katz Academy of Translational Research. No other conflicts of interest relevant to the content of this manuscript were reported by the authors.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/8
Y1 - 2022/8
N2 - PURPOSE OF REVIEW: The burden of obesity worldwide is high and projected to rise. Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk factors; hence, utilizing effective long-term therapies for obesity is of utmost importance. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective therapies that achieve substantial weight loss and improve cardiometabolic risk. The purpose of this review is to discuss the role of GLP-1RAs in obesity management.RECENT FINDINGS: Two subcutaneous GLP-1RAs, liraglutide and semaglutide, have been evaluated in several clinical trials for weight loss. Liraglutide achieves a mean weight loss of 4-7 kg, and more than 50% of treated individuals achieve 5% or more weight loss. Semaglutide has a greater impact on weight loss, with a mean weight loss of 9-16 kg, and more than 50% of treated individuals achieve 10-15% or more weight loss. These results led to regulatory approval of these agents for weight loss in individuals with obesity, regardless of diabetes status. In addition to weight loss, the benefits of GLP-1RAs extend to other risk factors, such as glycemic control and blood pressure. Gastrointestinal symptoms are the most frequently encountered adverse events with incidences between 5 and 30%. Finally, the cost remains one of the most critical challenges that limit GLP-1RAs use. GLP-1RAs have robust weight loss benefits and are expected to have a critical role in the management of obesity in the coming years. Upcoming studies will evaluate the durability of weight loss achieved with GLP-1RAs and the impact on cardiovascular outcomes.
AB - PURPOSE OF REVIEW: The burden of obesity worldwide is high and projected to rise. Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk factors; hence, utilizing effective long-term therapies for obesity is of utmost importance. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective therapies that achieve substantial weight loss and improve cardiometabolic risk. The purpose of this review is to discuss the role of GLP-1RAs in obesity management.RECENT FINDINGS: Two subcutaneous GLP-1RAs, liraglutide and semaglutide, have been evaluated in several clinical trials for weight loss. Liraglutide achieves a mean weight loss of 4-7 kg, and more than 50% of treated individuals achieve 5% or more weight loss. Semaglutide has a greater impact on weight loss, with a mean weight loss of 9-16 kg, and more than 50% of treated individuals achieve 10-15% or more weight loss. These results led to regulatory approval of these agents for weight loss in individuals with obesity, regardless of diabetes status. In addition to weight loss, the benefits of GLP-1RAs extend to other risk factors, such as glycemic control and blood pressure. Gastrointestinal symptoms are the most frequently encountered adverse events with incidences between 5 and 30%. Finally, the cost remains one of the most critical challenges that limit GLP-1RAs use. GLP-1RAs have robust weight loss benefits and are expected to have a critical role in the management of obesity in the coming years. Upcoming studies will evaluate the durability of weight loss achieved with GLP-1RAs and the impact on cardiovascular outcomes.
KW - Cardiovascular risk factors
KW - Glucagon-like peptide 1 receptor agonists
KW - Liraglutide
KW - Obesity
KW - Semaglutide
KW - Weight loss
KW - Obesity Management
KW - Humans
KW - Diabetes Mellitus, Type 2/drug therapy
KW - Weight Loss
KW - Glucagon-Like Peptide-1 Receptor/agonists
KW - Obesity/complications
KW - Hypoglycemic Agents/therapeutic use
KW - Liraglutide/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85130848774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130848774&partnerID=8YFLogxK
U2 - 10.1007/s11883-022-01041-7
DO - 10.1007/s11883-022-01041-7
M3 - Review article
C2 - 35624390
AN - SCOPUS:85130848774
SN - 1523-3804
VL - 24
SP - 643
EP - 654
JO - Current Atherosclerosis Reports
JF - Current Atherosclerosis Reports
IS - 8
ER -